The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)-Reference-Cited by-同舟云学术

The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)

Published:2017-06 Issue: Volume:104 Page:150-159
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Crawford E. David,Petrylak Daniel P.,Shore Neal,Saad Fred,Slovin Susan F.,Vogelzang Nicholas J.,Keane Thomas E.,Koo Phillip J.,Gomella Leonard G.,O'Sullivan Joe M.,Tombal Bertrand,Concepcion Raoul S.,Sieber Paul,Stone Nelson N.,Finkelstein Steven E.,Yu Evan Y.

Publisher

Elsevier BV

Subject

Urology

Reference53 articles.

1. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3;Scher;J Clin Oncol,2016

2. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline;Basch;J Clin Oncol,2014

3. Castration-resistant prostate cancer: AUA guideline amendment;Cookson;J Urol,2015

4. Challenges and recommendations for early identification of metastatic disease in prostate cancer;Crawford;Urology,2014

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra;Cancers;2024-07-29

2. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines;Cell Death & Disease;2023-05-09

3. Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII);JU Open Plus;2023-03

4. Transglutaminase-2 regulates mucin-1 expression and androgen independency in prostate cancer cell lines via an alternative truncated isoform;2022-11-21

5. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study;The Lancet Oncology;2022-11